Gen QA

MEMBER LOGIN

MENU menu

Close close menu

BRCA testing for ovarian, breast, prostate and pancreatic cancer - germline

BACK TO EQA DIRECTORY

BRCA1 and BRCA2 testing and interpretation in ovarian, breast, prostate and pancreatic cancer to determine treatment with PARP inhibitors - germline.

EQA INFORMATION

EQA Code
TBG
Submission
Clinical Report
Techniques
Any methodology
Eligibility
All laboratories worldwide. 
Language
English, French, German, Italian, Polish, Portuguese, Spanish
EQA Accreditation
EQA accredited to ISO 17043:2023
EQA open

22 September 2025

Testing period
8 weeks

OTHER INFORMATION

This EQA is sponsored by MSD and AstraZeneca, and offered in collaboration with EMQN - please do not enrol with both EQA providers.

What are participants required to do?
  • Enrolled participants will receive details by email when an EQA is open for assessment and/or samples have been dispatched.  
  • Participants are expected to access the instructions and information for the cases/samples online and to analyse them according to their laboratory/centre protocols. 
  • Participants must submit their anonymised results by the deadline using their standard laboratory report or a proforma provided by GenQA.  The submitted results are independently assessed for the accuracy of the analytical/genotyping results, clinical interpretation of the results (if appropriate) and clerical accuracy (including report layout and content). 

What can I expect as a participant?
Every participant will receive:
  • An Individual Laboratory/Centre Report (ILR/ICR) with educational advice for each distribution of this EQA.
  • The Summary report for each distribution of this EQA which contains information regarding general findings, a summary of methodologies used, common errors, number of participants and benchmarking. 
  • Access to a live Performance Certificate summarising your performance status for all EQAs in which you are enrolled.
 
Please note: EQA details may be subject to change prior to EQA distribution. 

PRODUCTS

Sample type: DNA in TE buffer
Testing/analysis: This EQA assesses the testing of BRCA1 and BRCA2 and the interpretation of results with respect to treatment options in addition to genetic interpretation.
Conditions/Gene target(s):
  • Ovarian cancer
  • Breast cancer
  • Prostate cancer
  • Pancreatic cancer
  • BRCA1. BRCA2  
Number of cases: Three

PURCHASE NOW

 

ASK A QUESTION

BRCA testing for ovarian, breast, prostate and pancreatic cancer - germline

Enter your details here: